Maxim Group Keeps Their Hold Rating on Kintara Therapeutics (KTRA)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Kintara Therapeutics (KTRAResearch Report). The company’s shares opened today at $0.09.

McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Actinium Pharmaceuticals, and SCYNEXIS. According to TipRanks, McCarthy has an average return of -39.6% and a 14.32% success rate on recommended stocks.

Kintara Therapeutics has an analyst consensus of Hold.

See Insiders’ Hot Stocks on TipRanks >>

KTRA market cap is currently $8.41M and has a P/E ratio of -0.27.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Read More on KTRA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More